Free Trial
NASDAQ:COGT

Cogent Biosciences Q2 2024 Earnings Report

Cogent Biosciences logo
$7.22 -0.04 (-0.55%)
As of 06/12/2025 04:00 PM Eastern

Cogent Biosciences EPS Results

Actual EPS
-$0.59
Consensus EPS
-$0.56
Beat/Miss
Missed by -$0.03
One Year Ago EPS
-$0.59

Cogent Biosciences Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Cogent Biosciences Announcement Details

Quarter
Q2 2024
Time
Before Market Opens
Conference Call Date
Tuesday, August 6, 2024
Conference Call Time
8:15AM ET

Upcoming Earnings

Cogent Biosciences' Q2 2025 earnings is scheduled for Tuesday, August 5, 2025, with a conference call scheduled at 8:15 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Cogent Biosciences Earnings Headlines

"I'm risking my reputation on this"
Behind closed doors, away from the mainstream media's eyes, the smartest minds in crypto are all seeing the same signals. They're positioning themselves for something unprecedented. And after 17 million podcast downloads and over 600 insider interviews, I finally connected all the dots… What I discovered was so explosive, so potentially life-changing, that I had to put it all in a book.
Cogent Biosciences appoints Ray Frost as SVP, Market Access
See More Cogent Biosciences Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Cogent Biosciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Cogent Biosciences and other key companies, straight to your email.

About Cogent Biosciences

Cogent Biosciences (NASDAQ:COGT), a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.

View Cogent Biosciences Profile

More Earnings Resources from MarketBeat